Zerit

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
27-03-2019
产品特点 产品特点 (SPC)
27-03-2019
公众评估报告 公众评估报告 (PAR)
02-06-2016

有效成分:

stavudine

可用日期:

Bristol-Myers Squibb Pharma EEIG

ATC代码:

J05AF04

INN(国际名称):

stavudine

治疗组:

Antivirals for systemic use

治疗领域:

HIV Infections

疗效迹象:

Hard capsulesZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.Powder for oral solutionZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.

產品總結:

Revision: 31

授权状态:

Withdrawn

授权日期:

1996-05-08

资料单张

                                57
B. PACKAGE LEAFLET
Approved
1.0
v
58
PACKAGE LEAFLET: INFORMATION FOR THE USER
ZERIT 15 MG HARD CAPSULES
Stavudine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Zerit is and what it is used for
2.
What you need to know before you take Zerit
3.
How to take Zerit
4.
Possible side effects
5.
How to store Zerit
6.
Contents of the pack and other information
1.
WHAT ZERIT IS AND WHAT IT IS USED FOR
Zerit belongs to a particular group of antiviral medicines, also known
as antiretrovirals, called
nucleoside reverse transcriptase inhibitors (NRTIs).
These are used to treat Human Immunodeficiency Virus (HIV) infection.
This medicinal product, in combination with other antiretrovirals,
reduces the HIV viral load and
keeps it at a low level. It also increases CD4 cell counts. These CD4
cells play an important role in
maintaining a healthy immune system to help fight infection. Response
to treatment with Zerit varies
between patients. Your doctor will therefore be monitoring the
effectiveness of your treatment.
Zerit may improve your condition, but it is not a cure for your HIV
infection. You can still pass on
HIV when taking this medicine, although the risk is lowered by
effective antiretroviral therapy.
Discuss with your doctor the precautions needed to avoid infecting
other people.
During treatment, other infections linked to a weakened immunity
(opportunistic infections) may arise.
These will require specific and sometimes preventive treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZERIT

                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Approved
1.0
v
2
1.
NAME OF THE MEDICINAL PRODUCT
Zerit 15 mg hard capsules
Zerit 20 mg hard capsules
Zerit 30 mg hard capsules
Zerit 40 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Zerit 15 mg hard capsules
Each hard capsule contains 15 mg of stavudine.
Excipients with known effect
Each hard capsule contains 80.84 mg of lactose anhydrous.
Each hard capsule contains 40.42 mg of lactose monohydrate.
Zerit 20 mg hard capsules
Each hard capsule contains 20 mg of stavudine.
Excipients with known effect
Each hard capsule contains 121.30 mg of lactose anhydrous.
Each hard capsule contains 60.66 mg of lactose monohydrate.
Zerit 30 mg hard capsules
Each hard capsule contains 30 mg of stavudine.
Excipients with known effect
Each hard capsule contains 121.09 mg of lactose anhydrous.
Each hard capsule contains 60.54 mg of lactose monohydrate.
Zerit 40 mg hard capsules
Each hard capsule contains 40 mg of stavudine.
Excipients with known effect
Each hard capsule contains 159.06 mg of lactose anhydrous.
Each hard capsule contains 79.53 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule.
Zerit 15 mg hard capsules
The hard capsule is red and yellow, opaque and imprinted with
“BMS” over a BMS code “1964” on
one side and “15” on the other side.
Zerit 20 mg hard capsules
The hard capsule is brown, opaque and imprinted with “BMS” over a
BMS code “1965” on one side
and “20” on the other side.
Zerit 30 mg hard capsules
The hard capsule is light and dark orange, opaque and imprinted with
“BMS” over a BMS code
“1966” on one side and “30” on the other side.
Approved
1.0
v
3
Zerit 40 mg hard capsules
The hard capsule is dark orange, opaque and imprinted with “BMS”
over a BMS code “1967” on one
side and “40” on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Zerit is indicated in combination with other antiretroviral medicinal
products for the treatmen
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 27-03-2019
产品特点 产品特点 保加利亚文 27-03-2019
公众评估报告 公众评估报告 保加利亚文 02-06-2016
资料单张 资料单张 西班牙文 27-03-2019
产品特点 产品特点 西班牙文 27-03-2019
公众评估报告 公众评估报告 西班牙文 02-06-2016
资料单张 资料单张 捷克文 27-03-2019
产品特点 产品特点 捷克文 27-03-2019
公众评估报告 公众评估报告 捷克文 02-06-2016
资料单张 资料单张 丹麦文 27-03-2019
产品特点 产品特点 丹麦文 27-03-2019
公众评估报告 公众评估报告 丹麦文 02-06-2016
资料单张 资料单张 德文 27-03-2019
产品特点 产品特点 德文 27-03-2019
公众评估报告 公众评估报告 德文 02-06-2016
资料单张 资料单张 爱沙尼亚文 27-03-2019
产品特点 产品特点 爱沙尼亚文 27-03-2019
公众评估报告 公众评估报告 爱沙尼亚文 02-06-2016
资料单张 资料单张 希腊文 27-03-2019
产品特点 产品特点 希腊文 27-03-2019
公众评估报告 公众评估报告 希腊文 02-06-2016
资料单张 资料单张 法文 27-03-2019
产品特点 产品特点 法文 27-03-2019
公众评估报告 公众评估报告 法文 02-06-2016
资料单张 资料单张 意大利文 27-03-2019
产品特点 产品特点 意大利文 27-03-2019
公众评估报告 公众评估报告 意大利文 02-06-2016
资料单张 资料单张 拉脱维亚文 27-03-2019
产品特点 产品特点 拉脱维亚文 27-03-2019
公众评估报告 公众评估报告 拉脱维亚文 02-06-2016
资料单张 资料单张 立陶宛文 27-03-2019
产品特点 产品特点 立陶宛文 27-03-2019
公众评估报告 公众评估报告 立陶宛文 02-06-2016
资料单张 资料单张 匈牙利文 27-03-2019
产品特点 产品特点 匈牙利文 27-03-2019
公众评估报告 公众评估报告 匈牙利文 02-06-2016
资料单张 资料单张 马耳他文 27-03-2019
产品特点 产品特点 马耳他文 27-03-2019
公众评估报告 公众评估报告 马耳他文 02-06-2016
资料单张 资料单张 荷兰文 27-03-2019
产品特点 产品特点 荷兰文 27-03-2019
公众评估报告 公众评估报告 荷兰文 02-06-2016
资料单张 资料单张 波兰文 27-03-2019
产品特点 产品特点 波兰文 27-03-2019
公众评估报告 公众评估报告 波兰文 02-06-2016
资料单张 资料单张 葡萄牙文 27-03-2019
产品特点 产品特点 葡萄牙文 27-03-2019
公众评估报告 公众评估报告 葡萄牙文 02-06-2016
资料单张 资料单张 罗马尼亚文 27-03-2019
产品特点 产品特点 罗马尼亚文 27-03-2019
公众评估报告 公众评估报告 罗马尼亚文 02-06-2016
资料单张 资料单张 斯洛伐克文 27-03-2019
产品特点 产品特点 斯洛伐克文 27-03-2019
公众评估报告 公众评估报告 斯洛伐克文 02-06-2016
资料单张 资料单张 斯洛文尼亚文 27-03-2019
产品特点 产品特点 斯洛文尼亚文 27-03-2019
公众评估报告 公众评估报告 斯洛文尼亚文 02-06-2016
资料单张 资料单张 芬兰文 27-03-2019
产品特点 产品特点 芬兰文 27-03-2019
公众评估报告 公众评估报告 芬兰文 02-06-2016
资料单张 资料单张 瑞典文 27-03-2019
产品特点 产品特点 瑞典文 27-03-2019
公众评估报告 公众评估报告 瑞典文 02-06-2016
资料单张 资料单张 挪威文 27-03-2019
产品特点 产品特点 挪威文 27-03-2019
资料单张 资料单张 冰岛文 27-03-2019
产品特点 产品特点 冰岛文 27-03-2019
资料单张 资料单张 克罗地亚文 27-03-2019
产品特点 产品特点 克罗地亚文 27-03-2019
公众评估报告 公众评估报告 克罗地亚文 02-06-2016

搜索与此产品相关的警报

查看文件历史